Board of Directors
Richard H. Aldrich
Chairman of the Board
Co-Founder and Partner, Longwood Founders Fund
Richard H. Aldrich is our co-founder and has served as a member of our board of directors and as
Chairman of our board of directors since May 2006. Mr. Aldrich is a Founder and has been Partner of
Longwood Fund, a venture capital firm, since February 2010. Mr. Aldrich founded RA Capital
Management LLC, a hedge fund, in 2004 and served as a Managing Member from 2004 to 2008 and as
a Co-Founding Member from 2008 until 2011. Mr. Aldrich has co-founded several biotechnology
companies including Sirtris Pharmaceuticals, Inc., which was acquired by GlaxoSmithKline in 2008, and
Alnara Pharmaceuticals, Inc., which was acquired by Eli Lilly in 2011. He has also held management
positions at Vertex, where he was a co-founding employee, and Biogen Corporation (now Biogen Idec
Inc., a biotechnology company). Mr. Aldrich co-founded and serves on the board of directors of
Verastem, Inc., a public biopharmaceutical company and also serves on the boards of directors of
OvaScience, Inc., a public life sciences company of which he serves as chairman of the board, and PTC
Therapeutics, Inc., a public biopharmaceutical company. Mr. Aldrich received his undergraduate degree
from Boston College, and an M.B.A. from the Amos Tuck School at Dartmouth College. We believe
Mr. Aldrich’s broad-based experience in business, including his leadership and board experience at life
science companies, and his familiarity with our business as a co-founder of our company allows him to
be a key contributor to our board of directors.
[ back to top ]
Ronald W. Barrett, Ph.D.
Chief Executive Officer, XenoPort, Inc.
Ronald W. Barrett, Ph.D. has served as a member of our board of directors since December 2007.
Dr. Barrett is a founder of XenoPort, Inc., a public biopharmaceutical company, and has served as its
Chief Executive Officer since 2001, its Chief Scientific Officer from 1999 to 2001 and as a member of its
board of directors since 1999. Prior to XenoPort he held various positions at Affymax Research Institute,
a drug discovery company now owned by GlaxoSmithKline plc, and Abbott Laboratories, a healthcare
company. Dr. Barrett received a B.S. from Bucknell University and a Ph.D. in pharmacology from
Rutgers University. We believe that Dr. Barrett’s industry and board experience, including his experience
as the chief executive officer of a publically traded biopharmaceutical company, makes him a key
contributor to our board of directors.
[ back to top ]
John G. Freund, M.D.
Managing Director, Skyline Ventures
John G. Freund, M.D. has served as a member of our board of directors since December 2013. Dr. Freund co-founded Skyline Ventures in 1997 and has served as a partner at Skyline since its founding. Prior to joining Skyline, Dr. Freund served as managing director in the private equity group of Chancellor Capital Management, a private capital investment firm. In 1995, he co-founded Intuitive Surgical, a medical device company, and served on its board of directors until 2000. From 1988 to 1994, Dr. Freund served in various positions at Acuson Corporation, a maker of ultrasound equipment that is now part of Siemens, most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a general partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988, Dr. Freund was a general partner at Morgan Stanley & Co., an investment banking company, where he co-founded the Healthcare Group in the Corporate Finance Department in 1983. He has served on the board of directors of XenoPort, Inc., a publicly traded biopharmaceutical company, since 1999, and Tetraphase Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, since 2012. Dr. Freund also serves on the board of directors of two privately held companies, Advion and DiscoverX, and three U.S. registered investment funds managed by Capital Research and Management. He also previously served on the board of directors of four publicly traded companies, Map Pharmaceuticals, a biopharmaceutical company, Hansen Medical, a biotechnology company, Sirtris Pharmaceuticals, a biopharmaceutical company, and Mako Surgical Corp., a medical device company. Dr. Freund is a member of the Advisory Board for the Harvard Business School Healthcare Initiative, and is a member of the Therapeutics Advisory Council of Harvard Medical School. Dr. Freund received a B.A. in history from Harvard College, an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School. We believe that Dr. Freund’s extensive finance and investment experience, his experience as an executive and his service on the board of directors of numerous public and privately held companies allows him to be a key contributor to our board of directors.
[ back to top ]
Peter Barton Hutt
Senior Counsel, Covington & Burling LLP
Peter Barton Hutt has served as a member of our board of directors since December 2006. Mr. Hutt has
practiced law at Covington & Burling LLP, specializing in food and drug law, since 1960 (except for the
period from 1971 to 1975) and currently serves as senior counsel. From 1971 to 1975 he was
Chief Counsel for the Food and Drug Administration. Mr. Hutt is a member of the board of directors of
Momenta Pharmaceuticals, Inc., a public pharmaceutical company, DBV Technologies SA,
Q Therapeutics, Inc. and Xoma Ltd., each of which is a public biotechnology company, as well as
numerous private companies. During the last five years, Mr. Hutt also served as a member of the board
of directors of Celera Genomics, a public biotechnology company that was acquired by Quest
Diagnostics, Inc. in 2011, CV Therapeutics, Inc., a public biotechnology company that was acquired by
Gilead Sciences, Inc. in 2009, and Ista Pharmaceuticals, Inc., a public pharmaceuticals company that was
acquired by Bausch & Lomb Inc. in 2012. Mr. Hutt received a B.A. from Yale University, an LL.B. from
Harvard Law School and an LL.M. from New York University School of Law. We believe Mr. Hutt’s
extensive knowledge of regulatory and legal issues related to drug development and his service on
numerous boards of directors allows him to be a key contributor to our board of directors.
[ back to top ]
Wilfred E. Jaeger, M.D.
Partner, Three Arch Partners
Wilfred E. Jaeger, M.D. has served as a member of our board of directors since May 2006. Dr. Jaeger
co-founded Three Arch Partners, a venture capital firm, in 1993 and has served as a Partner since that
time. Prior to co-founding Three Arch Partners, Dr. Jaeger was a general partner at Schroder Ventures.
He is also a member of the board of directors of Threshold Pharmaceuticals, Inc., a public
pharmaceutical company, as well as numerous private companies. Dr. Jaeger received a B.S. in Biology
from the University of British Columbia, his M.D. from the University of British Columbia School of
Medicine and an M.B.A. from Stanford University. In addition to representing one of our principal
stockholders, we believe that that Dr. Jaeger’s financial and medical knowledge and experience allows
him to be a key contributor to our board of directors.
[ back to top ]
Helmut M. Schühsler, Ph.D.
Managing Partner, TVM Capital
Helmut M. Schühsler, Ph.D. has served as a member of our board of directors since September 2011.
Dr. Schühsler has worked for TVM Capital, a group of life science venture capital and healthcare private
equity firms, since 1990 and currently serves as its Chairman and Managing Partner. During 2007 and 2008, Dr. Schühsler also served as Chairman of the European Private Equity and Venture Capital Association. Dr. Schühsler currently serves as a member of the board of Enanta Pharmaceuticals, Inc., a public pharmaceutical company, several other healthcare growth companies and Max Planck Innovation, the technology transfer organization of the German Max Planck Society. For several years he was a member of the Selection Committee for the Technology Pioneers program. Prior to joining TVM Capital, Dr. Schühsler worked for Horizonte Venture Management, a venture capital firm, and was an assistant professor for corporate finance at the Institute for Advanced Studies in Vienna. Dr. Schühsler received a Ph.D. in the Social and Economic Sciences from the University of Economics in Vienna. In addition to representing one of our principal stockholders, we believe that Dr. Schühsler’s business and financial experience as a director and investor in several companies in our industry allows him to be a key contributor to our board of directors.
[ back to top ]
Roger D. Tung, Ph.D.
President and CEO, Concert Pharmaceuticals, Inc.
Roger D. Tung, Ph.D. is our co-founder and has served as our President and Chief Executive Officer and
as a member of our board of directors since April 2006. Before Concert, Dr. Tung was a founding
scientist at Vertex, a pharmaceutical company, where he was employed from 1989 to 2005, most
recently as its Vice President of Drug Discovery. Prior to Vertex, he held various positions at Merck,
Sharp & Dohme Research Laboratories, a global healthcare provider, and The Squibb Institute for
Medicinal Chemistry. Dr. Tung received a B.A. in Chemistry from Reed College and a Ph.D. in
Medicinal Chemistry at the University of Wisconsin-Madison. We believe that Dr. Tung’s detailed
knowledge of our company and his 28 year career in the global pharmaceutical and biotechnology
industries, including his roles at Vertex, provide a critical contribution to our board of directors.
[ back to top ]